Supramolecular nano composite microneedle as well as preparation method and application thereof
By using supramolecular nanocomposite microneedles prepared by combining upconversion nanocomplexes and supramolecular action compounds, the existing microneedles are solved in the treatment of keloids, and the rapid dissolution and precise treatment are achieved, improving the Treatment effects and safety.
Patent Information
- Application Number
- CN202411135103.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-19
- Publication Date
- 2024-11-29
AI Technical Summary
The existing soluble microneedles have problems such as chain tangling, slow dissolution, and difficulty in encapsulating hydrophobic drugs when treating keloids, resulting in limited treatment effects and high recurrence rates.
Supramolecular nanocomposite microneedles prepared based on upconversion nanocomposites and compounds that can produce supramolecular effects have excellent mechanical properties and upconversion luminescent characteristics, can quickly dissolve and dissociate in water, encapsulate various drugs, And display visible light under near-infrared light excitation.
It realizes rapid dissolution and rapid release of supramolecular nanocomposite microneedles, has high strength, high toughness and good biocompatibility, can effectively pierce the skin and achieve precise treatment, reducing the recurrence rate.
Smart Images

Figure CN119033669A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of functional materials, and in particular relates to a supramolecular nanocomposite microneedle, a preparation method and application thereof. Background Art
[0002] Proliferative diseases such as keloids are a common pathological scar in genetically susceptible individuals, which manifests as invasive growth, that is, the lesion range exceeds the original injury boundary and is difficult to regress spontaneously. It is a disease type unique to humans, and the incidence rate has obvious racial differences. The etiology and pathogenesis of keloids are still unclear and are related to factors such as genetic susceptibility, increased skin tension, hypoxia, persistent inflammation, and autoimmunity. At present, the main treatments for keloids include surgical excision combined with radiotherapy, corticosteroid injection, laser therapy, cryotherapy, and chemotherapy. However, these treatment options have limited cure rates and high recurrence rates. Therefore, it is of great significance to develop an integrated diagnosis and treatment method to achieve minimally invasive, precise, intelligent, and efficient treatment of keloids.
[0003] Soluble microneedles are important carriers for the diagnosis and treatment of keloids. They are usually made of non-crystalline, water-soluble, and high-molecular-weight polymers with sufficient mechanical strength to penetrate the skin. However, polymer-based soluble microneedles still have many limitations, including: (1) high-molecular-weight polymers are prone to chain entanglement, which increases the viscosity of the solution and makes it difficult to prepare soluble microneedles; (2) existing soluble microneedles dissolve slowly in the skin, and the loaded drugs take a long time to take effect, making it difficult to meet the requirements of rapid diagnosis and treatment; (3) existing water-soluble polymers are difficult to encapsulate hydrophobic clinical drugs (accounting for more than 40% of existing clinical drugs). Summary of the invention
[0004] In view of one or more of the above defects or improvement needs of the prior art, the present invention provides a supramolecular nanocomposite microneedle, a preparation method and application thereof. The supramolecular nanocomposite microneedle is prepared based on a composite of an upconversion nanocomposite and a compound capable of producing supramolecular effects. The supramolecular nanocomposite microneedle has excellent mechanical properties and upconversion luminescence characteristics, can be quickly dissolved in an aqueous system, and has excellent biological safety.
[0005] To achieve the above object, according to one aspect of the present invention, a supramolecular nanocomposite microneedle is provided, wherein the supramolecular nanocomposite microneedle is prepared by compounding an upconversion nanocomposite with a compound capable of producing supramolecular effects;
[0006] The mass ratio of the up-conversion nanocomposite to the compound capable of producing supramolecular action is 1:100 to 1:10000.
[0007] As a further improvement of the present invention, the upconversion nanocomposite comprises upconversion nanoparticles and aqueous photosensitive polymers coated on the surface of the upconversion nanoparticles;
[0008] The up-conversion nanoparticles can generate visible light under near-infrared light excitation; the water-based photosensitizing polymer is a water-based polymer modified by a photosensitizer; the absorption spectrum of the photosensitizer at least partially overlaps with the emission spectrum of the up-conversion nanoparticles.
[0009] As a further improvement of the present invention, the upconversion nanoparticles are of a core-shell structure, the core of the upconversion nanoparticles is Na1nF4, wherein ln is selected from at least one of Y, Yb, Tm, Er, and Ho, and the shell of the upconversion nanoparticles is inert NaYbF4; and / or,
[0010] The aqueous polymer is at least one of polyethylene glycol, polyethylene imine, polyacrylic acid, polymethacrylic acid, polyacrylamide, and hyaluronic acid; and / or,
[0011] The photosensitizer is at least one of rose bengal, temoporfin, chlorophyll a, pheophorbide a, chlorin e6, pyropheophorbide a, and pyropheophorbide a.
[0012] As a further improvement of the present invention, the compound capable of producing supramolecular effects is a compound capable of producing at least one of hydrogen bonding, van der Waals forces, ion-π interactions, hydrophobic interactions, π-π stacking, electrostatic effects, host-guest effects, and inclusion complexes;
[0013] Preferably, the compound capable of producing supramolecular effects is at least one of cyclodextrin and its derivatives, calixarene and its derivatives, cucurbitacine and its derivatives, and pillararene and its derivatives.
[0014] As a further improvement of the present invention, the time for the supramolecular nanocomposite microneedle to dissolve in the skin model is less than 30 seconds; and / or,
[0015] The supramolecular nanocomposite microneedle has morphological integrity and morphological stability within a compression force range of 0.05N to 80N.
[0016] As a further improvement of the present invention, the supramolecular nanocomposite microneedles are arranged in an array, the distance between adjacent microneedle tips is 200-500 μm, and a single microneedle is conical with a base width of 200-600 μm and a height of 600-1200 μm.
[0017] According to a second aspect of the present invention, a method for preparing a supramolecular nanocomposite microneedle is provided, the method comprising the following steps:
[0018] S1. Preparation of upconversion nanocomposites;
[0019] Covalently linking a photosensitizer with a waterborne polymer to obtain a waterborne photosensitizer; coating the waterborne photosensitizer on the surface of upconversion nanoparticles to obtain the upconversion nanocomposite;
[0020] S2, preparing a matrix solution for supramolecular nanocomposite microneedles;
[0021] Dissolving the compound capable of producing supramolecular action and the upconversion nanocomposite in S1 in water and mixing them evenly to obtain a matrix solution of the supramolecular nanocomposite microneedle;
[0022] The mass ratio of the upconversion nanocomposite to the compound capable of producing supramolecular effects is 1:100 to 1:10000; the mass volume ratio of the compound capable of producing supramolecular effects to water is 0.1 to 10:1;
[0023] S3, preparation of supramolecular nano-microneedles;
[0024] The supramolecular nanocomposite microneedle matrix solution of S2 is added into a PDMS mold for vacuum treatment, and then the mold is removed after drying to obtain the supramolecular nanocomposite microneedle.
[0025] As a further improvement of the present invention, in S1,
[0026] The upconversion nanoparticles have a core-shell structure and can generate visible light under near-infrared light excitation; the core of the upconversion nanoparticles is Na1nF4, wherein ln is selected from at least one of Y, Yb, Tm, Er, and Ho, and the shell is inert NaYbF4; and / or,
[0027] The aqueous polymer is at least one of polyethylene glycol, polyethylene imine, polyacrylic acid, polymethacrylic acid, polyacrylamide, and hyaluronic acid; and / or,
[0028] The photosensitizer is at least one of rose bengal, temoporfin, chlorophyll a, pheophorbide a, chlorin e6, pyropheophorbide a, and pyropheophorbide a; and / or,
[0029] The compound capable of producing supramolecular effects is at least one of cyclodextrin and its derivatives, calixarene and its derivatives, cucurbitacin and its derivatives, and pillararene and its derivatives.
[0030] As a further improvement of the present invention, in S2, the viscosity of the supramolecular nanocomposite microneedle matrix solution is less than 0.3 Pa·s.
[0031] According to the third aspect of the present invention, there is provided an application of a supramolecular nanocomposite microneedle in the preparation of a transdermal drug delivery preparation, characterized in that the supramolecular nanocomposite microneedle is used, or the supramolecular nanocomposite microneedle is prepared by the preparation method;
[0032] Preferably, the transdermal administration preparation is a transdermal administration preparation for treating a proliferative disease.
[0033] The supramolecular nanocomposite microneedle of the present invention is prepared by compounding an upconversion nanocomposite and a compound capable of producing supramolecular effects. Based on supramolecular forces, the compound capable of producing supramolecular effects used in the present invention can encapsulate both hydrophobic and hydrophilic drugs. The supramolecular nanocomposite microneedle of the present invention has excellent mechanical strength and good toughness, and can effectively penetrate the stratum corneum of the skin to achieve transdermal drug delivery. At the same time, compared with traditional polymer microneedles, supramolecular nanocomposite microneedles are formed by non-covalent bonding, are easily dissociated in water, and the obtained solution exhibits a lower viscosity. The low viscosity of the composite matrix solution is beneficial to the preparation of supramolecular nanocomposite microneedles on the one hand, and is beneficial to the rapid dissociation of supramolecular nanocomposite microneedles after piercing the skin on the other hand, releasing the upconversion nanocomposite that plays a diagnostic and therapeutic role. In addition, the supramolecular nanocomposite microneedle has excellent upconversion luminescence performance under near-infrared light excitation, which not only allows real-time tracking of the diffusion behavior of the upconversion nanocomposite, but also enables precise treatment of lesions. In summary, the supramolecular nanocomposite microneedle described in the present invention has high strength, high toughness, high upconversion luminescence characteristics, good biocompatibility, and rapid dissolution in aqueous systems, with excellent comprehensive performance. As a carrier for transdermal drug delivery, it shows great application potential in the diagnosis and treatment of proliferative diseases (including but not limited to keloids).
[0034] In general, the above technical solution conceived by the present invention has the following beneficial effects compared with the prior art:
[0035] (1) The supramolecular nanocomposite microneedle of the present invention has excellent mechanical properties (high strength and high toughness) based on the synergy of multiple supramolecular effects, and can effectively pierce dense diseased tissues. Based on reversible and relatively weak supramolecular interactions, the soluble supramolecular nanocomposite microneedle has the characteristics of rapid dissolution and rapid release of the carried upconversion nanocomposite, which can be quickly effective and repeatedly administered in clinical applications.
[0036] (2) The supramolecular nanocomposite microneedle of the present invention has excellent upconversion luminescence properties and can monitor the release and diffusion of upconversion nanocomposites in real time under near-infrared light excitation.
[0037] (3) The present invention effectively balances the contradiction between high upconversion luminescence performance and high mechanical strength by optimizing the ratio of the upconversion nanocomposite and the compound capable of producing supramolecular effects.
[0038] (4) The matrix solution prepared by compounding the upconversion nanocomposite and the compound capable of producing supramolecular effects in the present invention exhibits extremely low viscosity, which makes it easier to operate and control during the processing and molding process. The prepared supramolecular nanocomposite microneedle maintains a complete morphology in appearance, and has a low molding shrinkage rate, showing dimensional stability and plasticity.
[0039] (5) The supramolecular nanocomposite microneedle of the present invention is used to prepare a transdermal drug delivery preparation, which has good biosafety, low skin irritation and minimally invasive characteristics, making the supramolecular nanocomposite microneedle an ideal transdermal drug delivery carrier, providing strong support for its safety and feasibility in drug delivery and biomedical applications. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 Graph showing the viscosity measurement results of supramolecular nanocomposite microneedle matrix solutions with different predetermined mass ratios in Example 1 of the present invention;
[0041] Figure 2 The pictures of the supramolecular nanocomposite microneedle of Example 1 of the present invention; wherein (A) is the overall morphology of the supramolecular nanocomposite microneedle (optical photo); (B) is the local bright field image (microscopic bright field) of the supramolecular nanocomposite microneedle; (C) is the morphology image (SEM) of the supramolecular nanocomposite microneedle by scanning electron microscopy imaging;
[0042] Figure 3 Characterization of the mechanical properties of supramolecular nanocomposite microneedles with different predetermined mass ratios in Example 1 of the present invention;
[0043] Figure 4 This is a graph showing the dissolution rate of the supramolecular nanocomposite microneedles prepared in Example 1 of the present invention in a modified gelatin skin model;
[0044] Figure 5 Characterization of the penetration depth of the supramolecular nanocomposite microneedle prepared in Example 1 of the present invention in the in vitro keloid tissue;
[0045] Figure 6 The wound healing process formed after the supramolecular nanocomposite microneedle prepared in Example 1 of the present invention is pressed on the surface of mouse skin;
[0046] Figure 7 This is a diagram showing the damage results of the supramolecular nanocomposite microneedle matrix solution prepared in Example 1 of the present invention on keloid fibroblasts. DETAILED DESCRIPTION
[0047] In order to make the purpose, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention. In addition, the technical features involved in the various embodiments of the present invention described below can be combined with each other as long as they do not conflict with each other.
[0048] The embodiment of the present invention provides a supramolecular nanocomposite microneedle, which is prepared by compounding an upconversion nanocomposite with a compound capable of producing supramolecular effects; the mass ratio of the upconversion nanocomposite to the compound capable of producing supramolecular effects is 1:100 to 1:10000.
[0049] The upconversion nanocomposite comprises upconversion nanoparticles and aqueous photosensitizing polymers coated on the surface thereof, wherein the upconversion nanoparticles can generate visible light under near-infrared light excitation; the aqueous photosensitizing polymers are aqueous polymers modified with photosensitizers; and the absorption spectrum of the photosensitizers at least partially overlaps with the spectrum of the upconversion nanoparticles.
[0050] Preferably, the orthogonal luminescence upconversion nanoparticles are of a core-shell structure, the core of the upconversion nanoparticles is Na1nF4, wherein In is selected from at least one of Y, Yb, Tm, Er, and Ho, and the shell of the upconversion nanoparticles is inert NaYbF4.
[0051] Preferably, the aqueous polymer is at least one of polyethylene glycol, polyethyleneimine, polyacrylic acid, polymethacrylic acid, polyacrylamide or hyaluronic acid; the photosensitizer is at least one of rose bengal, temoporfin, chlorophyll a, pheophorbide a, dihydrochlorin e6, pyropheophorbide a or pyropheophorbide a.
[0052] Preferably, the compound capable of producing supramolecular effects is a compound capable of producing at least one of hydrogen bonding, van der Waals forces, ion-π interactions, hydrophobic interactions, π-π stacking, electrostatic interactions, host-guest interactions, and inclusion complexes. More preferably, the compound capable of producing supramolecular effects is at least one of cyclodextrin and its derivatives (including but not limited to SCD), calixarene and its derivatives, cucurbitacin and its derivatives, and pillararene and its derivatives.
[0053] As a preferred embodiment of the present invention, the specific preparation method of the supramolecular nanocomposite microneedle prepared based on the composite of the upconversion nanocomposite and the compound capable of producing supramolecular action in the embodiment of the present invention comprises the following steps:
[0054] 1) Preparation of upconversion nanocomposites
[0055] Covalently linking the photosensitizer with the waterborne polymer through a chemical reaction to obtain a waterborne photosensitizer; coating the waterborne photosensitizer on the surface of upconversion nanoparticles to obtain an upconversion nanocomposite;
[0056] 2) Preparation of matrix solution for supramolecular nanocomposite microneedles
[0057] Dissolving the compound capable of producing supramolecular action and the upconversion nanocomposite in step 1) in water and mixing them evenly to obtain a matrix solution of supramolecular nanocomposite microneedles;
[0058] Preferably, the mass ratio of the upconversion nanocomposite to the compound capable of producing supramolecular effects is 1:100 to 1:10000; the mass volume ratio of the compound capable of producing supramolecular effects to water is 0.1 to 10:1.
[0059] In a specific embodiment of the present invention, a compound capable of producing supramolecular effects is first dissolved in deionized water to obtain an aqueous solution of the supramolecular compound, and then the upconversion nanocomposite and the aqueous solution of the supramolecular compound are uniformly mixed to obtain a matrix solution of supramolecular nanocomposite microneedles.
[0060] Specifically, a compound capable of producing supramolecular effects is added to deionized water, and stirred at room temperature until fully mixed to obtain an aqueous solution of the supramolecular compound; the stirring time is preferably 0.5 to 24 hours. Then, the upconversion nanocomposite is slowly added to the aqueous solution of the supramolecular compound according to a predetermined mass ratio, and stirred at room temperature for a predetermined time to obtain a matrix solution of supramolecular nanocomposite microneedles; the stirring time is preferably 0.5 to 24 hours.
[0061] However, it is understandable that methods of preparing the matrix solution of supramolecular nanocomposite microneedles, such as first adding the upconversion nanocomposite to water according to a set ratio and then adding the compound capable of producing supramolecular effect, or adding the upconversion nanocomposite and the compound capable of producing supramolecular effect to water together according to a set ratio, are all within the protection scope of the present invention, as long as the upconversion nanocomposite and the compound capable of producing supramolecular effect can be dissolved in water and mixed evenly.
[0062] Preferably, the viscosity of the prepared supramolecular nanocomposite microneedle matrix solution is less than 0.3 Pa·s.
[0063] 3) Preparation of supramolecular nanocomposite microneedles
[0064] The predetermined volume of supramolecular nanocomposite microneedle matrix solution in step 3) is dripped into the PDMS mold using a pipette for vacuum treatment, and after drying to remove the moisture in the supramolecular nanocomposite microneedle matrix solution, the mold is demoulded to obtain supramolecular nanocomposite microneedles.
[0065] The PDMS microneedle mold can be an existing mold or a mold prepared by an existing method. In a preferred embodiment, a method for preparing a PDMS microneedle mold is provided, comprising the following steps:
[0066] The PDMS prepolymer precursor and curing agent are mixed in a mass ratio of 10:1 to obtain the PDMS prepolymer. During the mixing process, the mixture is thoroughly stirred to ensure uniform mixing, and the bubbles are removed by vacuum to improve the preparation quality. The uniformly mixed PDMS prepolymer is added dropwise to a cell culture dish with a flat surface to ensure that the prepolymer is evenly coated on the entire bottom of the culture dish. Then, the culture dish coated with the PDMS prepolymer is placed on a flat stage, placed in an oven, and left to stand at 60-80°C for 2-4 hours to completely cure the PDMS. Finally, laser etching technology is used to accurately etch the surface of the PDMS substrate according to the set microneedle array pattern to form microneedle grooves. Through laser etching technology, precise control and customized design of microneedles can be achieved.
[0067] Preferably, in step 4), the predetermined volume of the supramolecular nanocomposite microneedle matrix solution is 100-500 μL; the array of supramolecular nanocomposite microneedles is preferably arranged in an array (such as a 10×10 array arrangement), the distance between adjacent microneedle tips is 200-500 μm, and a single microneedle is conical with a base width of 200-600 μm and a height of 600-1200 μm.
[0068] The technical solution of the present invention is further described below by enumerating embodiments, but the present invention is not limited to these embodiments.
[0069] It should be noted that in the supramolecular nanocomposite microneedles of the embodiments of the present invention, the preparation method of the upconversion nanocomposite itself adopts the existing mature technology, and its specific preparation method itself is not the innovation of the present invention. The innovation of the present invention lies in the use of upconversion nanocomposite and a compound capable of producing supramolecular effects to prepare supramolecular nanocomposite microneedles. It is only necessary to ensure that the types of upconversion nanoparticles, water-based polymers and photosensitizers in the upconversion nanocomposite are within the protection scope of the present invention. Exemplarily, the following Examples 1 to 3 specifically provide the preparation processes of three different upconversion nanocomposites. In the following specific embodiments, the core of the upconversion nanoparticles is composed of lanthanide rare earth elements Er, Yb and Tm, and the shell is composed of lanthanide rare earth element Yb, and detailed descriptions are given.
[0070] Example 1
[0071] This embodiment provides a kind of upconversion nanocomposite (UCNPs@PEI-RB@PEG-HKN 15 ) and supramolecular compound (SCD) prepared supramolecular nanocomposite microneedle, the specific preparation steps are as follows:
[0072] (1) Preparation of upconversion nanoparticles
[0073] In a 50 mL three-necked flask containing oleic acid (3 mL) and octadecene (7 mL), an aqueous solution (2 mL) containing Er (CH3CO2) 3 and Tm (CH3CO2) 3 was added. The mixture was heated at 150 ° C for 1 hour to form a lanthanide oleic acid complex and cooled to room temperature. Subsequently, a methanol solution containing NaOH (1 mmol) and NH4F (1.6 mmol) was added, stirred at 50 ° C for 0.5 hour, and then heated at 290 ° C under argon for 1.5 hours and cooled to room temperature. The resulting nanoparticle cores were collected by centrifugation, washed with cyclohexane and ethanol, and finally dispersed in cyclohexane for further use.
[0074] In a 50 mL flask containing oleic acid (3 mL) and octadecene (7 mL), an aqueous solution (2 mL) containing Y(CH3CO2)3, Yb(CH3CO2)3 was added in the designed ratio (50:50 mol%), and the total amount of lanthanide was 0.4 mmol. It was then heated at 150°C for 1 hour with magnetic stirring and then cooled at room temperature. Subsequently, NaErF4:Tm (0.5 mol%) nanoparticle cores were added as seeds along with 6 mL of NH4F (1.6 mmol) and NaOH (1 mmol) in methanol. The reaction mixture was stirred at 50°C for 0.5 hour, then heated at 290°C under argon for 1.5 hours and then cooled to room temperature. The product was collected by centrifugation, washed with cyclohexane and ethanol, and dispersed in cyclohexane for further use.
[0075] (2) Preparation of PEI-RB
[0076] A solution containing 0.2 mg of RB (Rose Bengal), 2 mg of EDC and 0.5 mg of NHS was reacted in a DMF solution for 30 minutes, and then 20 mg of PEI was added, and the mixed solution was reacted in the dark for 16 hours. The solution was dialyzed with PBS for 48 hours, and the product was finally dispersed in the PBS solution.
[0077] (3)NHS-PEG-HKN 15 Preparation
[0078] 10 mg of NHS-PEG-HKN 15 The product was stirred with 50 mg of PEI in DMSO solution for 24 hours and dialyzed with PBS for 48 hours, and finally dispersed in PBS solution.
[0079] (4) Upconversion nanocomposites (UCNPs@PEI-RB@PEG-HKN 15 )
[0080] First, 50 mg of NOBF4 was dissolved in a DMF solution. Subsequently, the upconversion nanoparticle solution dispersed in 10 mL of cyclohexane in step (1) was added to the DMF solution, vigorously stirred for 6 hours at room temperature, centrifuged at 10000 g for 10 minutes, and the product was dispersed in DMF for use. Subsequently, PEI-RB (25 mg) in step (2) was added to the DMF dispersion of UCNPs (10 mL, 5 mg / mL), stirred for 30 minutes, and centrifuged at 12000 g for 10 minutes to obtain UCNPs@PEI-RB.
[0081] Then, the NHS-PEG-HKN 15 (10 mg) was added to the aqueous solution of UCNPs@PEI-RB (50 mg). After stirring for 6 hours, UCNPs@PEI-RB@PEG-HKN was obtained by centrifugation at 12000 g for 10 minutes. 15 .
[0082] (5) Supramolecular nanocomposite microneedle matrix solution (UCNPs@PEI-RB@PEG-HKN 15 Preparation of SCD
[0083] 1.5 g of sulfobutyl ether-β-cyclodextrin (SCD) was dissolved in 1 mL of deionized water under magnetic stirring at room temperature, and then 0, 2.5, 5, 10, and 20 mg of nanocomplex (UCNPs@PEI-Chlorophylla@HA) were added respectively and stirred thoroughly to obtain uniform and transparent supramolecular nanomatrix solutions with upconversion nanocomplex concentrations of 0, 2.5, 5, 10, and 20 mg / mL.
[0084] (6) Preparation of supramolecular nanocomposite microneedles
[0085] The supramolecular nanomatrix solutions of different concentrations were filled into the PDMS mold (a cone array with a specification of 10×10, a single needle tip height of about 900μm, a needle tip base width of about 350μm, and a distance between adjacent needle tips of about 500μm), evacuated to -0.10MPa and left to stand for 20min. Subsequently, the PDMS mold containing the matrix solution was placed in a desiccant containing a desiccant and dried at room temperature for 24h. After drying, it was peeled off from the flexible PDMS mold to obtain supramolecular nanocomposite microneedles.
[0086] Example 2
[0087] This embodiment provides a supramolecular nanocomposite microneedle prepared based on an upconversion nanocomposite (UCNPs@PEI-Chlorophylla@PEG-GE11) and a supramolecular compound (calixarene). The preparation method is basically the same as that of Example 1, except that:
[0088] Step (2) is the preparation of PEI-Chlorophylla
[0089] 1.5 mg of chlorophyll-a (Chlorophylla), 10 mg of EDC and 5 mg of NHS were reacted in DMF solution for 30 minutes, and then 70 mg of PEI was added, and the mixed solution was reacted in the dark for 16 hours. It was dialyzed with PBS for 48 hours, and the product was finally dispersed in PBS solution.
[0090] Step (3) is the preparation of NHS-PEG-GE11
[0091] 10 mg of NHS-PEG-HKN 15 The product was stirred with 50 mg of PEI in DMSO solution for 24 hours and dialyzed with PBS for 48 hours, and finally dispersed in PBS solution.
[0092] Step (4) is the preparation of upconversion nanocomposite UCNPs@PEI-Chlorophylla@PEG-GE11
[0093] First, 50 mg of NOBF4 was dissolved in a DMF solution. Subsequently, the upconversion nanoparticle solution dispersed in 10 mL of cyclohexane in step (1) was added to the DMF solution, vigorously stirred for 6 hours at room temperature, centrifuged at 20,000 g for 30 minutes, and the product was dispersed in DMF for use. Subsequently, PEI-Chlorophylla (0.25 mg) in step (2) was added to the DMF dispersion of UCNPs (10 mL, 2.5 mg / mL), stirred for 30 minutes, and centrifuged at 15,000 g for 20 minutes to obtain UCNPs-PEI-Chlorophylla.
[0094] Then, NHS-PEG-GE11 (15 mg) in step (3) was added to the aqueous solution of UCNPs-PEI-Chlorophylla (50 mg), stirred for 12 hours, and centrifuged at 12000 g for 10 minutes to obtain UCNPs@PEI-Chlorophylla@PEG-GE11.
[0095] Step (5) is the preparation of supramolecular nanocomposite microneedle matrix solution (UCNPs@PEI-Chlorophylla@PEG-GE11)
[0096] 1.5 g of calixarene was dissolved in 1 mL of deionized water under magnetic stirring at room temperature, and then 5 mg of the nanocomposite (UCNPs@PEI-Chlorophylla@HA) was added and stirred thoroughly to obtain a uniform and transparent supramolecular nanomatrix solution.
[0097] Example 3
[0098] This embodiment provides a supramolecular nanocomposite microneedle prepared based on an upconversion nanocomposite (UCNPs@PEI-Chlorophylla@HA) and a supramolecular compound (pillar aromatics). The preparation method is basically the same as that of Example 1, except that:
[0099] Step (2) is the preparation of PEI-Temoporf
[0100] 0.7 mg of Temoporf, 7 mg of EDC and 5 mg of NHS were reacted in a DMF solution for 30 minutes, and then 140 mg of PEI was added, and the mixed solution was reacted in the dark for 16 hours. It was dialyzed with PBS for 48 hours, and the product was finally dispersed in the PBS solution.
[0101] Step (4) is the preparation of upconversion nanocomposite UCNPs@PEI-Chlorophylla@HA, wherein the aqueous polymer is hyaluronic acid HA;
[0102] First, 50 mg of NOBF4 was dissolved in a DMF solution. Subsequently, the upconversion nanoparticle solution dispersed in 10 mL of cyclohexane in step (1) was added to the DMF solution, vigorously stirred for 6 hours at room temperature, centrifuged at 17000 g for 20 minutes, and the product was dispersed in DMF for use. Subsequently, PEI-Temoporf (5 mg) in step (2) was added to the DMF dispersion of UCNPs (10 mL, 5 mg / mL), stirred for 30 minutes, and centrifuged at 12000 g for 13 minutes to obtain UCNPs@PEI-Chlorophylla.
[0103] Next, hyaluronic acid (HA; 10 mg) was added to the aqueous solution of UCNPs@PEI-Chlorophylla (50 mg), stirred for 10 hours, and centrifuged at 12000 g for 10 minutes to obtain UCNPs@PEI-Chlorophylla@HA.
[0104] Step (5) is the preparation of supramolecular nanocomposite microneedle matrix solution (UCNPs@PEI-Chlorophylla@HA)
[0105] 10.0 g of pillararenes were dissolved in 1 mL of deionized water under magnetic stirring at room temperature, and then 1 mg of nanocomposite (UCNPs@PEI-Chlorophylla@HA) was added and stirred thoroughly to obtain a uniform and transparent supramolecular nanomatrix solution.
[0106] Experimental Example 1: Viscosity Detection of Supramolecular Nanocomposite Microneedle Matrix Solution
[0107] The viscosity of the microneedle matrix solution prepared in Example 1 was measured using a rotational rheometer, which is an instrument widely used to measure the rheological properties of liquids and soft materials. During the experiment, the temperature was controlled at 25°C and the shear rate was varied from 100 to 1000 s -1 Through this series of tests, the viscosity characteristics of the microneedle matrix solution can be accurately understood, providing important reference and data support for subsequent preparation work.
[0108] Figure 1 The viscosity of the supramolecular nanocomposite microneedle matrix solution with different predetermined mass ratios in Example 1 is measured. This figure shows that the supramolecular nanocomposite microneedle matrix solution has a viscosity of UCNPs@PEI-RB@PEG-HKN 15 When the concentration increased from 0 mg / mL to 5 mg / mL, the viscosity of the supramolecular nanomatrix solution slowly decreased from 0.275 Pa·s to 0.115 Pa·s. 15 When the concentration increased from 5 mg / mL to 20 mg / mL, the viscosity of the supramolecular nanomatrix solution slowly increased from 0.115 Pa·s to 0.257 Pa·s. At the same time, compared with the polymer (PVP, PVA, PAA, HA and CMC) soluble microneedle solutions commonly used in the prior art, the supramolecular nanocomposite microneedle matrix solution of the embodiment of the present invention has a lower viscosity. The low-viscosity supramolecular nanomatrix solution helps to better fill the microneedle mold, ensuring that the supramolecular nanocomposite microneedle is easy to prepare and has a complete structure. In addition, the low-viscosity supramolecular nanomatrix solution helps the microneedle to better distribute and release UCNPs@PEI-RB@PEG-HKN in the skin tissue. 15 .
[0109] Figure 2 The figure is a picture of the supramolecular nanocomposite microneedle of Example 1, which shows that the needle body height of the synthesized supramolecular nanocomposite microneedle is about 900 μm, the distance between adjacent needle tips is about 500 μm, and the width of the needle body bottom is about 350 μm. These dimensions are comparable to the original size of the PDMS microneedle mold, indicating that the soluble supramolecular nanocomposite microneedle shrinks relatively little after drying.
[0110] Experimental Example 2: Mechanical properties test of supramolecular nanocomposite microneedles;
[0111] The compression force-displacement curves of supramolecular nanocomposite microneedles and polymer microneedles were obtained by applying pressure to the microneedle tip using a universal tensile testing machine (CMT 4104, Xinsansi, China). The initial distance between the microneedle and the sensor was fixed at 0.4 cm. The initial trigger force was 0.05 N and the maximum force was 80 N. The moving speed of the stainless steel plate was 0.5 mm / min.
[0112] Figure 3 The mechanical properties of the supramolecular nanocomposite microneedles with different predetermined mass ratios in Example 1 are characterized. The figure shows that the supramolecular nanocomposite microneedles with different concentrations do not have a compression fracture point in the experimental compression force range, indicating that they not only have excellent mechanical strength, but also have good toughness. This means that the supramolecular nanocomposite microneedles can maintain their integrity and morphological stability under certain pressure or force, and are not prone to fracture or deformation. Such characteristics enable the supramolecular nanocomposite microneedles to meet the needs of transdermal drug delivery for dense keloids, providing a reliable basis for their application in drug delivery.
[0113] Experimental Example 3: Detection of dissolution rate of supramolecular nanocomposite microneedles;
[0114] This test example uses a modified gelatin hydrogel as a skin model to calculate the in vitro dissolution rate of soluble supramolecular nanocomposite microneedles. 3g of gelatin was dissolved in 7g of deionized water, dissolved at 40°C for 1h, and cured at 4°C for 8h to prepare a gelatin hydrogel. The soluble supramolecular nanocomposite microneedles were inserted into the prepared gelatin hydrogel and removed at predetermined time intervals. An optical microscope equipped with a camera was used to observe the change in the length of the microneedle tip.
[0115] Figure 4 The figure is a dissolution rate diagram of the supramolecular nanocomposite microneedle prepared in Example 1 in the modified gelatin skin model. The figure shows that the supramolecular nanocomposite microneedle exhibits an ultrafast dissolution rate in the gelatin skin model. After piercing the in vitro gelatin skin model for 5s, 10s and 30s, the microneedle tip can dissolve by 50%, 70% and 100%, respectively. This ultrafast dissolution rate is attributed to the fact that the solid supramolecular nanocomposite microneedle is fully in contact with the water in the gelatin after being pierced into the modified gelatin skin model, so that the supramolecular unit dissociates rapidly.
[0116] Experimental Example 4 Evaluation of supramolecular nanocomposite microneedle puncture performance;
[0117] The in vivo epidermal penetration ability of soluble supramolecular nanocomposite microneedles was evaluated on fresh ex vivo keloid skin. Specifically, a supramolecular nanocomposite microneedle patch (10×10 microneedle array) was placed on the epidermis of the keloid and pressed with the thumb for 2 minutes, and then the microneedles were removed. The skin state of the keloid was imaged and evaluated before and after the application of the supramolecular nanocomposite microneedles. Subsequently, the skin of the supramolecular nanocomposite microneedle intervention site was stained to further evaluate the penetration depth of the supramolecular nanocomposite microneedles in the keloid tissue.
[0118] Figure 5The penetration depth of the supramolecular nanocomposite microneedle prepared in Example 1 in the ex vivo keloid tissue is characterized. The figure shows that the surface of the human skin keloid treated with the supramolecular nanocomposite microneedle shows a complete 10×10 microneedle array, and the puncture rate is as high as 100%. This shows that the supramolecular nanocomposite microneedle has sufficient mechanical properties to successfully puncture the tough human skin keloid. At the same time, it was found that the puncture depth of the supramolecular nanocomposite microneedle in fresh human skin keloid was as high as 180μm. Considering that the thickness of the epidermis of human skin keloid is about 100μm, this shows that the supramolecular nanocomposite microneedle can not only pierce the epidermis of the keloid, but also directly reach the superficial dermis of the skin, and is expected to achieve effective delivery of the upconversion nanocomposite. These results collectively show that the supramolecular nanocomposite microneedle has superior mechanical properties, can effectively puncture and destroy the stratum corneum drug delivery barrier of human skin keloid, is an efficient transdermal drug delivery method and shows great clinical application potential.
[0119] Experimental Example 5: Evaluation of the biological safety of supramolecular nanocomposite microneedles;
[0120] The supramolecular nanocomposite microneedle was inserted vertically into the back skin of nude mice to a certain depth by pressing with the thumb for 2 minutes to evaluate the damage of supramolecular nanocomposite microneedle to the back skin of living nude mice. The skin reactions of nude mice were observed at different time points after the removal of supramolecular nanocomposite microneedle, including redness, swelling, pain, bleeding, ulcers, etc.
[0121] The biosafety of the supramolecular nanomatrix solution was evaluated by CCK-8 assay. Specifically, keloid fibroblasts were seeded in 96-well plates and incubated for 12 h at 37 °C and 5% CO2. Subsequently, the cells were treated with supramolecular nanomatrix solutions at different concentrations. After 24 h of co-incubation, the culture medium was discarded and replaced with 100 μL of fresh culture medium containing 10% CCK-8 solution. After incubation at 37 °C for 4 h, the absorption at 450 nm was measured using a microplate reader.
[0122] Figure 6 The wound healing process formed after the supramolecular nanocomposite microneedle prepared in Example 1 was pressed on the surface of mouse skin. The figure shows that the skin of nude mice was quickly repaired after the supramolecular nanocomposite microneedle was pierced, and the microchannels generated by microneedle puncture were completely healed within 30 minutes, and no persistent skin irritation reaction was observed. These results prove that the supramolecular nanocomposite microneedle has good biosafety, low skin irritation and minimally invasive characteristics as a transdermal drug delivery preparation, providing strong support for its safety and feasibility in clinical applications.
[0123] Figure 7This is a diagram showing the damage results of the supramolecular nanocomposite microneedle matrix solution prepared in Example 1 on keloid fibroblasts. The figure shows that when the concentration of the supramolecular nanomatrix material is in the range of 0.25-4 mg / mL, the cell survival rate of the keloid fibroblasts is maintained at more than 95%, indicating the good biosafety of the supramolecular nanomatrix material.
[0124] In summary, the supramolecular nanocomposite microneedle of the present invention has excellent mechanical properties, can easily pierce the epidermis of proliferative diseases (such as keloids), and achieve efficient transdermal drug delivery. At the same time, the supramolecular nanocomposite microneedle matrix solution has a low viscosity, and can quickly dissolve and diffuse after piercing the diseased tissue, which is conducive to the rapid release of the upconversion nanocomposite. In addition, the supramolecular nanocomposite microneedle as a transdermal drug delivery tool has good biosafety, low skin irritation and minimally invasive characteristics, which provides strong support for its safety and feasibility in clinical applications.
[0125] It will be easily understood by those skilled in the art that the above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A supramolecular nanocomposite microneedle, characterized in that: The supramolecular nanocomposite microneedle is prepared by combining an upconversion nanocomposite with a compound capable of producing supramolecular effects; The mass ratio of the up-conversion nanocomposite to the compound capable of producing supramolecular action is 1:100 to 1:10000.
2. The supramolecular nanocomposite microneedle according to claim 1, characterized in that: The upconversion nanocomposite comprises upconversion nanoparticles and aqueous photosensitive polymers coated on the surface of the upconversion nanoparticles; The up-conversion nanoparticles can generate visible light under near-infrared light excitation; the water-based photosensitizing polymer is a water-based polymer modified by a photosensitizer; the absorption spectrum of the photosensitizer at least partially overlaps with the emission spectrum of the up-conversion nanoparticles.
3. The supramolecular nanocomposite microneedle according to claim 2, characterized in that: The upconversion nanoparticles are of a core-shell structure, the core of the upconversion nanoparticles is Na1nF4, wherein ln is selected from at least one of Y, Yb, Tm, Er, and Ho, and the shell of the upconversion nanoparticles is inert NaYbF4; and / or, The aqueous polymer is at least one of polyethylene glycol, polyethylene imine, polyacrylic acid, polymethacrylic acid, polyacrylamide, and hyaluronic acid; and / or, The photosensitizer is at least one of rose bengal, temoporfin, chlorophyll a, pheophorbide a, chlorin e6, pyropheophorbide a, and pyropheophorbide a.
4. The supramolecular nanocomposite microneedle according to any one of claims 1 to 3, characterized in that: The compound capable of producing supramolecular effects is a compound capable of producing at least one of hydrogen bonding, van der Waals forces, ion-π interactions, hydrophobic interactions, π-π stacking, electrostatic interactions, host-guest interactions, and inclusion complexes; Preferably, the compound capable of producing supramolecular effects is at least one of cyclodextrin and its derivatives, calixarene and its derivatives, cucurbitacine and its derivatives, and pillararene and its derivatives.
5. The supramolecular nanocomposite microneedle according to any one of claims 1 to 3, characterized in that: The time for the supramolecular nanocomposite microneedle to dissolve in the skin model is less than 30 seconds; and / or, The supramolecular nanocomposite microneedle has morphological integrity and morphological stability within a compression force range of 0.05N to 80N.
6. The supramolecular nanocomposite microneedle according to any one of claims 1 to 3, characterized in that: The supramolecular nanocomposite microneedles are arranged in an array, the distance between adjacent microneedle tips is 200-500 μm, and a single microneedle is in a cone shape with a base width of 200-600 μm and a height of 600-1200 μm.
7. A method for preparing a supramolecular nanocomposite microneedle, characterized in that: The steps include: S1. Preparation of upconversion nanocomposites; Covalently linking a photosensitizer with a waterborne polymer to obtain a waterborne photosensitizer; coating the waterborne photosensitizer on the surface of upconversion nanoparticles to obtain the upconversion nanocomposite; S2, preparing a matrix solution for supramolecular nanocomposite microneedles; Dissolving the compound capable of producing supramolecular action and the upconversion nanocomposite in S1 in water and mixing them evenly to obtain a matrix solution of the supramolecular nanocomposite microneedle; The mass ratio of the upconversion nanocomposite to the compound capable of producing supramolecular effects is 1:100 to 1:10000; the mass volume ratio of the compound capable of producing supramolecular effects to water is 0.1 to 10:1; S3, preparation of supramolecular nano-microneedles; The supramolecular nanocomposite microneedle matrix solution of S2 is added into a PDMS mold for vacuum treatment, and then the mold is removed after drying to obtain the supramolecular nanocomposite microneedle.
8. The method for preparing the supramolecular nanocomposite microneedle according to claim 7, characterized in that: In S1, The upconversion nanoparticles have a core-shell structure and can generate visible light under near-infrared light excitation; the core of the upconversion nanoparticles is Na1nF4, wherein ln is selected from at least one of Y, Yb, Tm, Er, and Ho, and the shell is inert NaYbF4; and / or, The aqueous polymer is at least one of polyethylene glycol, polyethylene imine, polyacrylic acid, polymethacrylic acid, polyacrylamide, and hyaluronic acid; and / or, The photosensitizer is at least one of rose bengal, temoporfin, chlorophyll a, pheophorbide a, chlorin e6, pyropheophorbide a, and pyropheophorbide a; and / or, The compound capable of producing supramolecular effects is at least one of cyclodextrin and its derivatives, calixarene and its derivatives, cucurbitacin and its derivatives, and pillararene and its derivatives.
9. The method for preparing the supramolecular nanocomposite microneedle according to claim 7 or 8, characterized in that: In S2, the viscosity of the supramolecular nanocomposite microneedle matrix solution is less than 0.3 Pa·s.
10. Use of a supramolecular nanocomposite microneedle in preparing a transdermal drug delivery preparation, characterized in that: The supramolecular nanocomposite microneedle according to any one of claims 1 to 6 is used, or the supramolecular nanocomposite microneedle is prepared by the preparation method according to any one of claims 7 to 9; Preferably, the transdermal administration preparation is a transdermal administration preparation for treating a proliferative disease.
Citation Information
Patent Citations
Photosensitive controlled-release microneedle and preparation method thereof
CN114272374A
Supramolecular photosensitizer soluble microneedle as well as preparation method and application thereof
CN115252534A
Orthogonal up-conversion luminescence nanocomposite material, and preparation method and application thereof
CN116515485A
Non-invasive energy upconversion methods and systems for in-situ photobiomodulation
US20110021970A1
Microneedle compositions and methods of using same
US20170196966A1
